JP2021528368A - Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 - Google Patents

Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 Download PDF

Info

Publication number
JP2021528368A
JP2021528368A JP2020562120A JP2020562120A JP2021528368A JP 2021528368 A JP2021528368 A JP 2021528368A JP 2020562120 A JP2020562120 A JP 2020562120A JP 2020562120 A JP2020562120 A JP 2020562120A JP 2021528368 A JP2021528368 A JP 2021528368A
Authority
JP
Japan
Prior art keywords
alkyl
ocf
alkoxy
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020562120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528368A5 (cg-RX-API-DMAC7.html
Inventor
ジェフリー ジェイ． クラーク
ジョン オー． トレント
ジョセフ エー． バーリソン
Original Assignee
ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド filed Critical ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド
Publication of JP2021528368A publication Critical patent/JP2021528368A/ja
Publication of JP2021528368A5 publication Critical patent/JP2021528368A5/ja
Priority to JP2024022691A priority Critical patent/JP2024056937A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020562120A 2018-05-10 2019-05-10 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 Pending JP2021528368A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022691A JP2024056937A (ja) 2018-05-10 2024-02-19 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669926P 2018-05-10 2018-05-10
US62/669,926 2018-05-10
PCT/US2019/031885 WO2019217933A1 (en) 2018-05-10 2019-05-10 Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022691A Division JP2024056937A (ja) 2018-05-10 2024-02-19 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Publications (2)

Publication Number Publication Date
JP2021528368A true JP2021528368A (ja) 2021-10-21
JP2021528368A5 JP2021528368A5 (cg-RX-API-DMAC7.html) 2022-05-17

Family

ID=68467113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562120A Pending JP2021528368A (ja) 2018-05-10 2019-05-10 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Country Status (10)

Country Link
US (2) US12582660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3790541B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021528368A (cg-RX-API-DMAC7.html)
KR (1) KR20210009331A (cg-RX-API-DMAC7.html)
CN (1) CN112312901B (cg-RX-API-DMAC7.html)
AU (1) AU2019265011B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099148A1 (cg-RX-API-DMAC7.html)
IL (1) IL278596B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011991A (cg-RX-API-DMAC7.html)
WO (1) WO2019217933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117731785A (zh) * 2022-09-15 2024-03-22 上海交通大学医学院附属第九人民医院 一种用于治疗脉管畸形的载药乙醇可视化复合制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101919842A (zh) * 2009-06-11 2010-12-22 复旦大学 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用
JP2011506580A (ja) * 2007-12-21 2011-03-03 ピエール、ファーブル、メディカマン アルテミシニンの二量体誘導体、および抗癌療法における用途
WO2012073041A2 (en) * 2010-12-02 2012-06-07 The University Of Nottingham Compounds
JP2017538772A (ja) * 2014-12-16 2017-12-28 エーディーティー ファーマシューティカルズ，エルエルシー Ｒａｓ媒介性疾患を処置または予防する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233051A (ja) 1984-05-04 1985-11-19 Daicel Chem Ind Ltd ２−クロル−５−ニトロベンゼンスルホンアミドの製造方法
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
KR20010072591A (ko) * 1998-06-09 2001-07-31 추후보정 4급 암모늄 화합물 진해제
US20080139534A1 (en) * 2006-12-07 2008-06-12 Xavier University Of Louisiana Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis
WO2009013915A1 (ja) * 2007-07-25 2009-01-29 Renascience Co., Ltd. プラスミノーゲンアクチベーターインヒビター－１阻害剤
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
WO2011103435A2 (en) 2010-02-18 2011-08-25 The Board Of Trustees Of The University Of Illinois Methods for forming protected organoboronic acids
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
KR20120048223A (ko) 2010-11-05 2012-05-15 주식회사 이큐스앤자루 2-페닐-4-[3-(치환된-설포닐)아닐리노]퀴나졸린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물
WO2013042782A1 (ja) 2011-09-22 2013-03-28 武田薬品工業株式会社 縮合複素環化合物
WO2014037726A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Liquid pharmaceutical compositions
ES2491390B1 (es) * 2013-02-04 2015-06-22 Universidad Complutense De Madrid Nuevos inhibidores de la enzima isoprenilcisteina carboximetiltransferasa (icmt)
CN105283454B (zh) 2013-04-12 2019-10-29 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506580A (ja) * 2007-12-21 2011-03-03 ピエール、ファーブル、メディカマン アルテミシニンの二量体誘導体、および抗癌療法における用途
CN101919842A (zh) * 2009-06-11 2010-12-22 复旦大学 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用
WO2012073041A2 (en) * 2010-12-02 2012-06-07 The University Of Nottingham Compounds
JP2017538772A (ja) * 2014-12-16 2017-12-28 エーディーティー ファーマシューティカルズ，エルエルシー Ｒａｓ媒介性疾患を処置または予防する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[ONLINE], JPN7023001938, 2008, ISSN: 0005178567 *

Also Published As

Publication number Publication date
IL278596B2 (en) 2025-05-01
MX2020011991A (es) 2021-04-12
CN112312901A (zh) 2021-02-02
EP3790541B1 (en) 2024-12-04
JP2024056937A (ja) 2024-04-23
US20210137939A1 (en) 2021-05-13
WO2019217933A1 (en) 2019-11-14
KR20210009331A (ko) 2021-01-26
IL278596B1 (en) 2025-01-01
CN112312901B (zh) 2024-05-14
WO2019217933A8 (en) 2021-02-11
US20260232689A1 (en) 2026-08-13
EP3790541A4 (en) 2022-02-16
EP3790541A1 (en) 2021-03-17
IL278596A (cg-RX-API-DMAC7.html) 2020-12-31
AU2019265011A1 (en) 2020-11-26
CA3099148A1 (en) 2019-11-14
US12582660B2 (en) 2026-03-24
AU2019265011B2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
US12234226B2 (en) Compounds as nuclear transport modulators and uses thereof
JP7326622B2 (ja) Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用
CA3144859C (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
WO2024009191A1 (en) Pyrido[4,3-d]pyrimidine compounds
EP3416964B1 (en) 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
TWI699363B (zh) 四氫-吡啶并［３，４-ｂ］吲哚雌激素受體調節劑及其用途
JP2024056937A (ja) Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
CN112300145B (zh) 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用
CN118084905A (zh) 苯甲酰胺化合物
JP7660801B2 (ja) 脳透過性ｂｔｋ又はｈｅｒ２阻害剤としての化合物およびその製造方法と応用
JP2022019812A (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
TW202116770A (zh) 類鐸受體促效劑
US20190023684A1 (en) Substituted 5-cyanoindole compounds and uses thereof
US10501466B2 (en) WDR5 inhibitors and modulators
JP2019525960A (ja) ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
RU2800042C1 (ru) Спиросоединения в качестве ингибиторов ERK и их применение
TW202426441A (zh) 用於治療癌症之化合物
TW202547479A (zh) 驅動蛋白kif18a抑制劑及其使用方法
HK40039936A (en) Compounds as nuclear transport modulators and uses thereof
HK40039936B (en) Compounds as nuclear transport modulators and uses thereof
BR122025019374A2 (pt) Forma cristalina de composto de sulfonamida, sal de ácido benzoico, seus usos, seu método de preparação, composição farmacêutica que os compreende, e cocristal dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231023

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240216